Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients

Chinese Medical Journal

Volumn 124, Issue 19, 2011, Pages 2981-2985

  Hu, Yu ^a   Chen, Lei ^a   Sun, Chun yan ^a   She, Xiao mei ^a   Ai, Li sha ^a   Qin, You ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cytogenetics; Fluorescence in situ hybridization; Multiply myeloma; Prognosis; Progression free survival

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BORTEZOMIB; CALCIUM; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE MARROW CELL; CALCIUM BLOOD LEVEL; CHINESE; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 1Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; INTERPHASE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMA CELL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS;

EID: 80053481653     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.19.004     Document Type: Article

References (28)

1. Kaufmann H, Urbauer E, Ackermann J, Huber H, Drach J. Advances in the biology and therapeutic management of multiple myeloma. Ann Hematol 2001; 80: 445-451.
2. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-737.
3. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382-3387.
4. Qu XY, Fu WJ, Xi H, Zhou F, Wei W, Hou J. Clinical features of multiple myeloma invasion of the central nervous system in Chinese patients. Chin Med J 2010; 123: 1402-1406.
5. Gutierrez NC, Hernandez JM, GarciaJ L, Almeida J, Mateo G, Gonzalez MI, et al. Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells. Haematologica 2000; 85: 1146-1152.
6. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiplemyeloma: aworkshop report. Cancer Res 2004; 64: 1546-1558.
7. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-2238.
8. Calasanz MJ, Cigudosa JC, Odero MD, Garcia-Foncillas J, Marin J, Ardanaz MT, et al. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma. Br J Haematol 1997; 98: 418-425.
9. Fonseca R, Harrington D, Oken MM, Dewald GW, Balley RJ, Van Wier SA, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (D13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 2002; 62: 715-720.
10. Konigsberg R, Zojer N, Ackermann J, Kromer E, Fritz E, Kaufmann H, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18: 804-812.
11. Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: Durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-4010.
12. Shaughnessy J Jr, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003; 120: 44-52.
13. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724-1732.
14. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-4575.
15. Chang H, Sloan S, Li D, Keith SA. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127: 280-284.
16. Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CJ, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet 2006; 168: 124-132.
17. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12: 2955-2960.
18. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
19. Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multi-probe interphase FISH. Blood 2000; 96: 1505-1511.
20. Huang SY, Yao M, Tang JL, Tsay W, Lee FY, Liu MC, et al. Clinical significance of cytogenetics and interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol 2005; 16: 1530-1538.
21. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, Almeida J, Gonzalez M, Fernandez-Calvo J, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. Blood 1998; 91: 3366-3371.
22. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005; 44: 194-203.
23. Durie BG. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005; 6: 181-190.
24. Chang H, Trieu Y, Qi X, Jiang NN, Xu W, Reece D. Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leuk Res 2011; 35: 95-98.
25. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4634.
26. Klein U, Jauch A, Hielscher T, Hillengass J, Raab MS, Seckinger A, et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer 2011; 117: 2136-2144.
27. Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114: 522-525.
28. Ludwig H, Adam Z, Tóthová E, Hajek R, Labar B, Egyed M, et al. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica 2010; 95: 1548-1554.